[{"id":"ae2fe60f-b070-447a-b2c4-028f7bd0f6b4","acronym":"","url":"https://clinicaltrials.gov/study/NCT01042925","created_at":"2021-01-18T04:05:47.746Z","updated_at":"2024-07-02T16:37:31.530Z","phase":"Phase 1/2","brief_title":"Study of XL147 (SAR245408) in Combination With Trastuzumab or Paclitaxel and Trastuzumab in Subjects With Metastatic Breast Cancer Who Have Progressed on a Previous Trastuzumab-based Regimen","source_id_and_acronym":"NCT01042925","lead_sponsor":"Sanofi","biomarkers":" HER-2","pipe":" | ","alterations":" HER-2 positive • HER-2 overexpression","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 positive • HER-2 overexpression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Herceptin (trastuzumab) • paclitaxel • pilaralisib (SAR245408) • AP06 (trastuzumab biosimilar)"],"overall_status":"Completed","enrollment":" Enrollment 42","initiation":"Initiation: 02/01/2010","start_date":" 02/01/2010","primary_txt":" Primary completion: 12/01/2012","primary_completion_date":" 12/01/2012","study_txt":" Completion: 12/01/2012","study_completion_date":" 12/01/2012","last_update_posted":"2016-06-03"},{"id":"e56b349a-b69a-4109-9846-e2fd6587dab1","acronym":"","url":"https://clinicaltrials.gov/study/NCT01082068","created_at":"2021-01-18T04:16:01.865Z","updated_at":"2024-07-02T16:37:31.533Z","phase":"Phase 1/2","brief_title":"Study of XL147 (SAR245408) or XL765 (SAR245409) in Combination With Letrozole in Subjects With Breast Cancer","source_id_and_acronym":"NCT01082068","lead_sponsor":"Sanofi","biomarkers":" HER-2","pipe":"","alterations":" ","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e letrozole • pilaralisib (SAR245408) • voxtalisib (SAR245409)"],"overall_status":"Completed","enrollment":" Enrollment 72","initiation":"Initiation: 06/01/2010","start_date":" 06/01/2010","primary_txt":" Primary completion: 04/01/2013","primary_completion_date":" 04/01/2013","study_txt":" Completion: 04/01/2013","study_completion_date":" 04/01/2013","last_update_posted":"2016-06-03"}]